| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Lusvertikimab manufacturers
- Lusvertikimab
-
- $228.00
-
2026-07-27
- CAS:2375835-91-7
- Purity: 95.00%
- Supply Ability: 10g
|
| | Lusvertikimab Basic information |
| Product Name: | Lusvertikimab | | Synonyms: | Lusvertikimab;Research Grade Lusvertikimab (DHD19401);Research Grade Lusvertikimab;Lusvertikimab (anti-CD127) | | CAS: | 2375835-91-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lusvertikimab Structure]() |
| | Lusvertikimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lusvertikimab Usage And Synthesis |
| Uses | Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1]. | | in vivo | OSE-127 treated mice shows a reduction of peripheral blood (PB) blasts in 21/22 (95%) PDX samples in vivo when the corresponding control mice showed clinical signs of overt leukemia[1]. | | IC 50 | IL7R | | References | [1] Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS| NOVEMBER 15, 2022.
[2] Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjgren's Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640. DOI:10.1002/art.41558 |
| | Lusvertikimab Preparation Products And Raw materials |
|